Please note that the details of this Challenge are no longer open. This challenge is awarded and is no longer accepting new submissions. You can:
Challenge Biomarkers of Treatment Response in Retinal Neovascular Disease
Biomarkers of Treatment Response in Retinal Neovascular Disease
STATUS: Awarded
Active Solvers: 252
Posted: Sep 17 2013
Challenge ID: 9933454
Team Project Rooms are available on this Challenge Team Share Challenge Share

The Seeker wishes to understand novel biomarkers predictive of treatment efficacy in retinal neovascular disease. The marker(s) must be amenable to measurement from minimally invasive samples or procedures.

This Challenge requires only a written proposal.


A range of methods and markers exist to score diseases, such as wet age-related macular degeneration (AMD) in terms of their severity and also likelihood to respond to therapies. However, few relevant disease markers are measurable without highly invasive procedures such as vitreous humor sampling. Proposals describing minimally invasive markers that help predict response to anti-VEGF biological therapies are required. More specific information regarding the specific disease states and known markers are within the detailed challenge description.

This is a Theoretical Challenge that requires only a written proposal to be submitted.  The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.

To receive an award, the Solvers will not have to transfer their exclusive IP rights to the Seeker.  Instead, the Seeker will pay the award amount and the Solver will grant to the Seeker a perpetual, royalty-free non-exclusive worldwide license and first right of refusal for an exclusive license to practice their solutions in the field of eye diseases. The license and right of first refusal conditions are documented in the Challenge Specific Agreement.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is a Theoretical-Licensing Challenge?

An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.

This Challenge is a Theoretical-Licensing Challenge, meaning that the Seeker is requesting non-exclusive rights to use the winning solution. By contrast, Theoretical-IP Transfer means that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.

Share This Challenge